ArticleMedComm2025

Once-weekly glucagon-like peptide receptor agonist polyethylene glycol loxenatide protects against major adverse cardiovascular events in patients with type 2 diabetes: a multicenter ambispective cohort study (FLYING trial).

Jilin Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.